Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings.

Autor: Henick BS; Department of Medicine, Division of Hematology and Medical Oncology, Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center, New York, New York, USA bh2682@cumc.columbia.edu at3488@cumc.columbia.edu cas2145@cumc.columbia.edu., Koch PD; Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York, USA., Gainor JF; Department of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA., Awad MM; Department of Hematology/Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA., Chiuzan C; Department of Biostatistics, Northwell Health Feinstein Institutes for Medical Research, Manhasset, New York, USA., Izard S; Department of Biostatistics, Northwell Health Feinstein Institutes for Medical Research, Manhasset, New York, USA., Georgis Y; Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York, USA., Mallick S; Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York, USA., Garofano RF; Department of Medicine, Division of Hematology and Medical Oncology, Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center, New York, New York, USA., Wong CV; Department of Biomarker Development and Medical Affairs, Genentech-Roche, San Francisco, California, USA., Saqi A; Department of Medicine, Division of Hematology and Medical Oncology, Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center, New York, New York, USA., Grindheim J; Department of Biomarker Development and Medical Affairs, Genentech-Roche, San Francisco, California, USA., Schulze K; Department of Biomarker Development and Medical Affairs, Genentech-Roche, San Francisco, California, USA., Sonett JR; Department of Surgery, Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center, New York, New York, USA., Rizvi NA; Department of Medicine, Division of Hematology and Medical Oncology, Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center, New York, New York, USA., Izar B; Department of Medicine, Division of Hematology and Medical Oncology, Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center, New York, New York, USA., Taylor AM; Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York, USA bh2682@cumc.columbia.edu at3488@cumc.columbia.edu cas2145@cumc.columbia.edu., Shu CA; Department of Medicine, Division of Hematology and Medical Oncology, Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center, New York, New York, USA bh2682@cumc.columbia.edu at3488@cumc.columbia.edu cas2145@cumc.columbia.edu.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2024 Dec 25; Vol. 12 (12). Date of Electronic Publication: 2024 Dec 25.

Dissecting the treatment-naive ecosystem of human melanoma brain metastasis.

Autor: Biermann J; Department of Medicine, Division of Hematology/Oncology, and Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY 10032, USA; Program for Mathematical Genomics, Columbia University, New York, NY 10032, USA., Melms JC; Department of Medicine, Division of Hematology/Oncology, and Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY 10032, USA; Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, NY 10032, USA., Amin AD; Department of Medicine, Division of Hematology/Oncology, and Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY 10032, USA; Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, NY 10032, USA., Wang Y; Department of Medicine, Division of Hematology/Oncology, and Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY 10032, USA; Program for Mathematical Genomics, Columbia University, New York, NY 10032, USA., Caprio LA; Department of Medicine, Division of Hematology/Oncology, and Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY 10032, USA; Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, NY 10032, USA., Karz A; Department of Pathology, NYU Grossman School of Medicine, New York, NY 10016, USA., Tagore S; Department of Systems Biology, Columbia University Irving Medical Center, New York, NY 10032, USA., Barrera I; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA., Ibarra-Arellano MA; Heidelberg University, Faculty of Medicine, and Heidelberg University Hospital, Institute for Computational Biomedicine, Bioquant, 69120 Heidelberg, Germany., Andreatta M; Department of Oncology UNIL CHUV, Lausanne Branch, Ludwig Institute for Cancer Research Lausanne, CHUV and University of Lausanne, Lausanne, 1066 Épalinges, Switzerland; Swiss Institute of Bioinformatics, 1015 Lausanne, Switzerland., Fullerton BT; Department of Medicine, Division of Hematology/Oncology, and Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY 10032, USA., Gretarsson KH; Department of Genetics and Development, Columbia University Medical Center, New York, NY 10032, USA., Sahu V; Department of Genetics and Development, Columbia University Medical Center, New York, NY 10032, USA., Mangipudy VS; Department of Genetics and Development, Columbia University Medical Center, New York, NY 10032, USA., Nguyen TTT; Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY 10032, USA., Nair A; Department of Medicine, Division of Hematology/Oncology, and Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY 10032, USA., Rogava M; Department of Medicine, Division of Hematology/Oncology, and Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY 10032, USA; Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, NY 10032, USA., Ho P; Department of Medicine, Division of Hematology/Oncology, and Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY 10032, USA; Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, NY 10032, USA., Koch PD; Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA., Banu M; Department of Neurological Surgery, New York Presbyterian/Columbia University Irving Medical Center, New York, NY 10032, USA., Humala N; Department of Neurological Surgery, New York Presbyterian/Columbia University Irving Medical Center, New York, NY 10032, USA., Mahajan A; Department of Neurological Surgery, New York Presbyterian/Columbia University Irving Medical Center, New York, NY 10032, USA., Walsh ZH; Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA., Shah SB; Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA., Vaccaro DH; Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA., Caldwell B; Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA., Mu M; Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA., Wünnemann F; Heidelberg University, Faculty of Medicine, and Heidelberg University Hospital, Institute for Computational Biomedicine, Bioquant, 69120 Heidelberg, Germany., Chazotte M; Heidelberg University, Faculty of Medicine, and Heidelberg University Hospital, Institute for Computational Biomedicine, Bioquant, 69120 Heidelberg, Germany., Berhe S; Department of Medicine, Division of Hematology/Oncology, and Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY 10032, USA., Luoma AM; Department of Cancer Immunology and Virology, Dana-Farber Cancer Center, Boston, MA 02215, USA., Driver J; Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA., Ingham M; Department of Medicine, Division of Hematology/Oncology, and Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY 10032, USA., Khan SA; Department of Medicine, Division of Hematology/Oncology, and Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY 10032, USA., Rapisuwon S; Division of Hematology/Oncology, Medstar Washington Cancer Institute, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA., Slingluff CL Jr; Department of Surgery, University of Virginia, Charlottesville, VA, USA., Eigentler T; Department of Dermatology, Eberhard Karls University Tübingen, 72076 Tübingen, Germany; Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Dermatology, Venereology and Allergology, 10117, Berlin, Germany., Röcken M; Department of Dermatology, Eberhard Karls University Tübingen, 72076 Tübingen, Germany., Carvajal R; Department of Medicine, Division of Hematology/Oncology, and Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY 10032, USA., Atkins MB; Georgetown-Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA., Davies MA; Department of Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, TX 77030, USA., Agustinus A; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Pharmacology, Weill Cornell Graduate School, New York, NY 10065, USA., Bakhoum SF; Department of Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, TX 77030, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Azizi E; Department of Biomedical Engineering, Columbia University, New York, NY 10027, USA; Irving Institute for Cancer Dynamics, Columbia University, New York, NY 10027, USA., Siegelin M; Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY 10032, USA., Lu C; Department of Genetics and Development, Columbia University Medical Center, New York, NY 10032, USA., Carmona SJ; Department of Oncology UNIL CHUV, Lausanne Branch, Ludwig Institute for Cancer Research Lausanne, CHUV and University of Lausanne, Lausanne, 1066 Épalinges, Switzerland; Swiss Institute of Bioinformatics, 1015 Lausanne, Switzerland., Hibshoosh H; Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY 10032, USA., Ribas A; Department of Medicine, Jonsson Comprehensive Cancer Center, University of California, Los Angeles (UCLA), Los Angeles, CA 90024, USA., Canoll P; Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY 10032, USA., Bruce JN; Department of Neurological Surgery, New York Presbyterian/Columbia University Irving Medical Center, New York, NY 10032, USA., Bi WL; Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Agrawal P; Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York, NY 10461, USA., Schapiro D; Heidelberg University, Faculty of Medicine, and Heidelberg University Hospital, Institute for Computational Biomedicine, Bioquant, 69120 Heidelberg, Germany; Institute of Pathology, Heidelberg University Hospital, 69120 Heidelberg, Germany., Hernando E; Department of Pathology, NYU Grossman School of Medicine, New York, NY 10016, USA., Macosko EZ; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, USA., Chen F; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA., Schwartz GK; Department of Medicine, Division of Hematology/Oncology, and Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY 10032, USA., Izar B; Department of Medicine, Division of Hematology/Oncology, and Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY 10032, USA; Program for Mathematical Genomics, Columbia University, New York, NY 10032, USA; Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, NY 10032, USA. Electronic address: bi2175@cumc.columbia.edu.

Publikováno v: Cell [Cell] 2022 Jul 07; Vol. 185 (14), pp. 2591-2608.e30.

Chromatin bridges, not micronuclei, activate cGAS after drug-induced mitotic errors in human cells.

Autor: Flynn PJ; Department of Systems Biology, Harvard Medical School, Boston, MA 02115; patrick_flynn@hms.harvard.edu timothy_mitchison@hms.harvard.edu., Koch PD; Center for Systems Biology, Massachusetts General Hospital, Boston, MA 02114., Mitchison TJ; Department of Systems Biology, Harvard Medical School, Boston, MA 02115; patrick_flynn@hms.harvard.edu timothy_mitchison@hms.harvard.edu.

Publikováno v: Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2021 Nov 30; Vol. 118 (48).

Publisher Correction: Colchicine acts selectively in the liver to induce hepatokines that inhibit myeloid cell activation.

Autor: Weng JH; Department of Systems Biology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA. jui-hsia_weng@hms.harvard.edu., Koch PD; Department of Systems Biology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.; Center for Systems Biology, Massachusetts General Hospital, Boston, MA, USA., Luan HH; NGM Biopharmaceuticals, South San Francisco, CA, USA., Tu HC; Alnylam Pharmaceuticals, Inc., Cambridge, MA, USA., Shimada K; Department of Systems Biology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA., Ngan I; NGM Biopharmaceuticals, South San Francisco, CA, USA., Ventura R; NGM Biopharmaceuticals, South San Francisco, CA, USA., Jiang R; Department of Systems Biology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA., Mitchison TJ; Department of Systems Biology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA. timothy_mitchison@hms.harvard.edu.

Publikováno v: Nature metabolism [Nat Metab] 2021 May; Vol. 3 (5), pp. 728.

Mechanisms underlying the compromised clinical efficacy of interferon in clearing HBV.

Autor: Lei, Zhuoyan¹ (AUTHOR), Wang, Luye¹ (AUTHOR), Gao, Hanlin¹ (AUTHOR), Guo, Shubian¹ (AUTHOR), Kang, Xinjian¹ (AUTHOR), Yuan, Jiajun¹ (AUTHOR), Lv, Ziying¹ (AUTHOR), Jiang, Yuxin¹ (AUTHOR), Yi, Jinping² (AUTHOR), Chen, Zhi³ (AUTHOR), Wang, Gang¹ (AUTHOR) wg008@zjsru.edu.cn

Publikováno v: Virology Journal. 12/4/2024, Vol. 21 Issue 1, p1-13. 13p.